• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

SenzaGen

5.68 SEK

+1.07 %

Less than 1K followers

SENZA

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.07 %
+7.17 %
+10.51 %
-6.58 %
-6.58 %
-0.70 %
-49.73 %
-68.53 %
-86.56 %

Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.

Read more
Market cap
184.65M SEK
Turnover
1.37K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

18.2.
2027

Annual report '26

Press release09.06.2026 klo 08.30

SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million

SenzaGen
Press release05.06.2026 klo 08.30

EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential

SenzaGen
Regulatory press release12.05.2026 klo 16.25

Report from AGM of SenzaGen AB on 12 May 2026

SenzaGen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release12.05.2026 klo 08.30

SenzaGen’s interim report January–March 2026 | 10% sales growth alongside increased attention to non-animal methods

SenzaGen
Press release05.05.2026 klo 10.30

Invitation to the presentation of SenzaGen's January-March 2026 interim report

SenzaGen
Regulatory press release21.04.2026 klo 10.00

SenzaGen’s Annual Report 2025 published

SenzaGen
Press release15.04.2026 klo 08.30

SenzaGen’s subsidiary receives strategically important order

SenzaGen
Regulatory press release08.04.2026 klo 09.30

NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ)

SenzaGen
Press release30.03.2026 klo 08.30

SenzaGen wins new global cosmetics group as customer

SenzaGen
Press release17.03.2026 klo 08.30

SenzaGen to present strong GARD®skin data at the world’s largest toxicology conference together with leading industry partners

SenzaGen
Press release10.03.2026 klo 08.30

Growing interest in non-animal respiratory allergy testing – GARD®air data presented by industry leaders

SenzaGen
Regulatory press release13.02.2026 klo 09.00

SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group

SenzaGen
Regulatory press release13.02.2026 klo 08.30

SenzaGen’s Year-End Report 2025 | SenzaGen closes the year with continued strong GARD® sales

SenzaGen
Press release06.02.2026 klo 09.30

Invitation to the presentation of SenzaGen's year-end report 2025

SenzaGen
Press release16.12.2025 klo 08.30

SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader

SenzaGen
Press release20.11.2025 klo 08.30

SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan

SenzaGen
Press release19.11.2025 klo 09.39

BioStock: Video from SenzaGen's presentation at BioStock Life Science Summit 2025

SenzaGen
Press release18.11.2025 klo 12.20

UK signals shift to non-animal testing – new opportunities for SenzaGen

SenzaGen
Press release12.11.2025 klo 08.30

SenzaGen secures order worth SEK 2.5 million from leading global tech company

SenzaGen
Press release10.11.2025 klo 08.30

SenzaGen presents growth plan and strategic priorities at Capital Markets Day

SenzaGen